Sapanisertib, Carboplatin, and Paclitaxel in Treating Patients With Recurrent or Refractory Malignant Solid Tumors
Study Details
Study Description
Brief Summary
This phase I trial studies the sides effects and best dose of sapanisertib, carboplatin, and paclitaxel in treating patients with malignant solid tumors that have come back (recurrent) or do not respond to treatment (refractory). Sapanisertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing cells, by stopping them from dividing, or by stopping them from spreading. Giving sapanisertib, carboplatin, and paclitaxel may work better in treating patients with malignant solid tumors.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 1 |
Detailed Description
PRIMARY OBJECTIVE:
- To determine the safety and tolerability of the combination of sapanisertib (TAK-228 [MLN0128]) plus paclitaxel, when given with carboplatin, and to determine the optimal dose triplet, or maximum tolerated dose (MTD), in patients with advanced cancers refractory to standard therapy.
SECONDARY OBJECTIVES:
- To assess the clinical tumor response of this combination. II. To assess toxicity of this combination. III. To assess progression free survival. IV. To assess molecular signatures predictive of sensitivity and resistance.
OUTLINE: This is a dose escalation study.
Patients receive sapanisertib orally (PO) once daily (QD) on days 2-4, 9-11, and 16-18, paclitaxel intravenously (IV) over 3 hours on days 1, 8, and 15, and carboplatin IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive sapanisertib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up periodically.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Treatment (sapanisertib, paclitaxel, carboplatin) Patients receive sapanisertib PO QD on days 2-4, 9-11, and 16-18, paclitaxel IV over 3 hours on days 1, 8, and 15, and carboplatin IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive sapanisertib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. |
Drug: Carboplatin
Given IV
Other Names:
Drug: Paclitaxel
Given IV
Other Names:
Drug: Sapanisertib
Given PO
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Incidence and grade of adverse events graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v.) 4.03 [Up to 30 days after last dose]
Wilcoxon's Signed-Rank Test and Fisher's exact test will be used for data analysis of continuous variables and categorical variables, respectively. A mixed model accounting for patient effects will be used to analyze longitudinal data over time. Descriptive statistics will be provided on the grade and type of toxicity by dose level.
- Maximum tolerate dose (MTD) as defined by dose limiting toxicity (DLT) [Up to 21 days]
MTD is the highest dose level in which 6 patients have been treated with at most 1 experiencing DLT. DLT is defined as treatment-related grade 3 or greater non-hematological toxicity other than nausea, vomiting, or fatigue; drug-related grade 3 or greater clinically significant laboratory abnormalities that do not return to grade 1 or baseline within 72 hours; grade 3 nausea and vomiting related to study drug treatment that is not controlled for 72 hours despite appropriate antiemetic therapy; or grade 4 fatigue related to study drug therapy. Toxicities graded using the NCI CTCAE v. 4.03 toxicity criteria. Descriptive statistics will be provided on the grade and type of toxicity by dose level. This protocol will utilize a standard 3 + 3 design. Three patients will be treated per dose level.
- Death during the study [Up to 5 years]
A mixed model accounting for patient effects will be used to analyze longitudinal data over time.
- Withdrawals due to adverse events [Up to 5 years]
Adverse events graded using NCI CTCAE v. 4.03 toxicity criteria. Descriptive statistics will be provided on the grade and type of toxicity by dose level.
- Change in treatment regimen due to adverse events [Baseline up to 5 years]
Will assess changed of treatment regimen such as dose delay and dose reduction over time by dose level due to adverse events. Adverse events graded using NCI CTCAE v. 4.0 toxicity criteria. Descriptive statistics will be provided on the grade and type of toxicity by dose level.
- Recommended phase 2 dose (RP2D) [Up to 21 days]
The MTD or lower doses defined during the dose escalation phase will be expanded to further characterize the safety, clinical responses, and pharmacodynamic studies to define RP2D. In general, the MTD will be considered the RP2D.
Secondary Outcome Measures
- Clinical tumor response based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria [Up to 5 years]
All of the patients who meet the eligibility criteria will be included in the main analysis of the response rate. Patients in response categories 3-8 should be considered as failing to respond to therapy (disease progression). A patient will be determined as having a response if he/she has complete response (CR), partial response (PR). Additionally, a patient with CR, PR, or stable disease (SD) for at least 6 cycles will be considered as having clinical benefit. A patient will be determined as a non-response if there is SD for less than 6 cycles or no evidence of response by 6 cycles during this study. Wilcoxon's Signed-Rank Test and Fisher's exact test will be used for data analysis of continuous variables and categorical variables, respectively. A mixed model accounting for patient effects will be used to analyze longitudinal data over time. Descriptive statistics will be provided on the grade and type of toxicity by dose level.
- Progression-free survival as defined by RECIST v.1.1 [Up to 5 years]
- Molecular signatures predictive of sensitivity and resistance [Up to 5 years]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients must have a diagnosis of a solid tumor malignancy and is refractory to standard therapies who have relapsed after standard therapy, or whose cancers have no standard therapy.
-
Eastern Cooperative Oncology Group (ECOG) performance status and/or other performance status =< 1.
-
Female patients who: Are postmenopausal for at least 1 year before the screening visit, OR are surgically sterile, OR if they are of childbearing potential, agree to practice 1 effective method of contraception and 1 additional effective (barrier) method, at the same time, from the time of signing the informed consent through 90 days (or longer as mandated by local labeling [e.g., United Surgical Partners International (USPI), summary of product characteristics (SmPC), etc,]) after the last dose of study drug, OR agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the patient (Periodic abstinence [e.g., calendar, ovulation, symptothermal, postovulation methods], withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of contraception. Female and male condoms should not be used together.)
-
Male patients, even if surgically sterilized (i.e., status post-vasectomy), who: agree to practice highly effective barrier contraception during the entire study treatment period and through 120 days after the last dose of study drug, OR agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the patient. (Periodic abstinence [e.g., calendar, ovulation, symptothermal, postovulation methods for the female partner], withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of contraception. Female and male condoms should not be used together.) Agree not to donate sperm during the course of this study or within 120 days after receiving their last dose of study drug.
-
Absolute neutrophil count (ANC) >= 1.5 x 10^9/L.
-
Platelet count >= 100 x 10^9/L.
-
Hemoglobin >= 9 g/dL without transfusion within 1 week preceding study drug administration.
-
Total bilirubin =< 1.5 x upper limit of normal (ULN).
-
Transaminases (aspartate aminotransferase/serum glutamic oxaloacetic transaminase [AST/SGOT] and alanine aminotransferase/serum glutamic pyruvic transaminase [ALT/SGPT]) =< 2.5 x ULN (=< 5 x ULN if liver metastases are present).
-
Creatinine clearance >= 50 mL/min based either on Cockcroft-Gault estimate or based on urine collection (12 or 24 hour).
-
Glycosylated hemoglobin (HbA1c) < 7%.
-
Fasting serum glucose =< 130 mg/dL.
-
Fasting triglycerides =< 300 mg/dL.
-
Ability to swallow oral medications.
-
Voluntary written consent must be given before performance of any study related procedure not part of standard medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to future medical care.
-
Patients who have a history of brain metastasis are eligible for the study provided that all the following criteria are met: a) Brain metastases which have been treated
- No evidence of disease progression for >= 3 months before the first dose of study drug. c) No hemorrhage after treatment d) Off-treatment with dexamethasone for 4 weeks before administration of the first dose of TAK-228 e) No ongoing requirement for dexamethasone or anti-epileptic drugs.
-
Patients must have evaluable or measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria.
-
Patients must be 4 weeks beyond previous treatment of any chemotherapy or radiotherapy, and must have recovered to =< grade 1 or previous baseline for each toxicity. Exception: Patients may have received palliative low dose radiotherapy to the limbs 1-4 weeks before this therapy provided pelvis, sternum, scapulae, vertebrae, or skull were not included in the radiotherapy field. Patients who have received non-chemotherapeutic biological agents will need to wait at least 5 half-lives or 4 weeks, whichever is shorter, from the last day of treatment of non-chemotherapeutic biological agents.
Exclusion Criteria:
-
Carboplatin or paclitaxel exposure within past 6 months.
-
Central nervous system (CNS) metastasis.
-
Other clinically significant co-morbidities, such as uncontrolled pulmonary disease, active central nervous system disease, active infection, or any other condition that could compromise the patient's participation in the study.
-
Known history of human immunodeficiency virus infection.
-
Known history of hepatitis B surface antigen-positive, or known or suspected active hepatitis C infection.
-
Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol.
-
Diagnosed or treated for another malignancy within 2 years before administration of the first dose of study drug, or previously diagnosed with another malignancy and have any evidence of residual disease. Patients with non-melanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection.
-
Breast feeding or pregnant.
-
Treatment with any investigational products within 4 weeks before the first dose of study drug.
-
Previous treatment with dual PI3K/mTOR inhibitors, TORC1/2 inhibitors or TORC1 inhibitors.
-
Manifestations of malabsorption due to prior gastrointestinal (GI) surgery, GI disease, or for an unknown reason that may alter the absorption of TAK-228. In addition, patients with enteric stomata are also excluded.
-
History of any of the following within the last 6 months before administration of the first dose of the drug: a) Ischemic myocardial event, including angina requiring therapy and artery revascularization procedures b) Ischemic cerebrovascular event, including transient ischemic attack and artery revascularization procedures c) Requirement for inotropic support (excluding digoxin) or serious (uncontrolled) cardiac arrhythmia (including atrial flutter/fibrillation, ventricular fibrillation or ventricular tachycardia) d) Placement of a pacemaker for control of rhythm e) New York Heart Association (NYHA) class III or IV heart failure f) Pulmonary embolism.
-
Significant active cardiovascular or pulmonary disease including: a) Uncontrolled hypertension (i.e., systolic blood pressure > 150 mm Hg, diastolic blood pressure > 90 mm Hg). Use of anti-hypertensive agents to control hypertension before cycle 1 day 1 is allowed. b) Pulmonary hypertension c) Uncontrolled asthma or oxygen (O2) saturation < 90% by arterial blood gas analysis or pulse oximetry on room air d) Significant valvular disease; severe regurgitation or stenosis by imaging independent of symptom control with medical intervention, or history of valve replacement e) Medically significant (symptomatic) bradycardia f) History of arrhythmia requiring an implantable cardiac defibrillator g) Baseline prolongation of the rate-corrected QT interval (QTc) (e.g., repeated demonstration of QTc interval > 480 milliseconds, or history of congenital long QT syndrome, or torsades de pointes).
-
Poorly controlled diabetes mellitus defined as glycosylated hemoglobin (HbA1c) > 7%; patients with a history of transient glucose intolerance due to corticosteroid administration may be enrolled in this study if all other inclusion/exclusion criteria are met.
-
Patients receiving systemic corticosteroids (either IV or oral steroids, excluding inhalers or low-dose hormone replacement therapy) within 1 week before administration of the first dose of study drug.
-
Daily or chronic use of a proton pump inhibitor (PPI) and/or having taken a PPI within 7 days before receiving the first dose of study drug.
-
Patients with hypersensitivity or other allergic reaction to platinum chemotherapy.
-
Patients with hypersensitivity or other allergic reaction to taxanes.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | M D Anderson Cancer Center | Houston | Texas | United States | 77030 |
Sponsors and Collaborators
- M.D. Anderson Cancer Center
- National Cancer Institute (NCI)
Investigators
- Principal Investigator: Vivek Subbiah, M.D. Anderson Cancer Center
Study Documents (Full-Text)
None provided.More Information
Additional Information:
Publications
None provided.- 2016-0845
- NCI-2018-00989
- 2016-0845